Related Experiment Video
Updated: May 18, 2026
An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Anti-C5a Antibody STSA-1002 for Patients With ARDS Due to Viral Pneumonia: A Phase 1b/2, Multicenter, Randomized,
Yeming Wang1, Xiaobo Huang2, Zhenshun Cheng3
1Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Medicine of Capital Medical University, National Center for Respiratory Medicine, New Cornerstone Science Laboratory, State Key Laboratory of Respiratory Health and Multimorbidity, China-Japan Friendship Hospital, Beijing, China.
Background:
ARDS constitutes a major cause of mortality, with limited therapeutic options.
Research Question:
Is STSA-1002, an anti-C5a monoclonal antibody, safe and clinically beneficial in ARDS caused by viral pneumonia?
Study Design And Methods:
This was a phase 1b/2, multicenter, double-anonymizzed, placebo-controlled trial. Participants aged between 18 and 85 years with ARDS caused by viral pneumonia and Pao2/Fio2 ≤ 200 mm Hg were included. Patients were randomly assigned (1:1:1) to receive STSA-1002 1,350 mg, STSA-1002 750 mg, or placebo. The STSA-1002 or matched placebo was administered to participants on days 1, 3, and 7, with an optional additional dose on day 14 ± 1 at the physician's discretion. The primary end point was time to clinical improvement. Clinical improvement was defined as either blood oxygen saturation/Fio2 > 235 mm Hg or Pao2/Fio2 > 200 mm Hg, maintained for at least 48 hours, whichever occurred first, within 28 days.
Results:
Between December 9, 2023, and March 20, 2025, a total of 49 patients were enrolled and randomized to treatment. Among the 47 patients who received study medication, 17 received STSA-1002 1,350 mg, 15 received STSA-1002 750 mg, and 15 received placebo. The time to clinical improvement was 6.0 days in the STSA 1002 1,350 mg group, 8.4 days in the STSA 1002 750 mg group, and 7.4 days in the control group. A subdistribution hazard ratio of 1.55 (95% CI, 0.68-3.55) was reported for the STSA-1002 1,350 mg group and 1.04 (95% CI, 0.46-2.38) for the STSA-1002 750 mg group according to a competing risk model, both compared with the control group. Following adjustment for baseline Pao2/Fio2, the subdistribution hazard ratio was 1.22 (95% CI, 0.52-2.86) and 1.13 (95% CI, 0.47-2.75), respectively. The 28-day all-cause mortality was 5.88% (1 of 17), 26.67% (4 of 15), and 40% (6 of 15). STSA-1002 was well tolerated.
Interpretation:
STSA-1002 exhibited a favorable safety profile and potential efficacy. These findings warrant confirmation in a phase 3 trial.
Clinical Trial Registration:
ClinicalTrials.gov; No.: NCT06038916; URL: www.
Clinicaltrials:
gov.
More Related Videos
09:06Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
Published on: December 12, 2025
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Related Concept Videos
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:30Pneumonia III: Complications and Assessment
01:30Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause: